{"prompt": "['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', '12.3.3 Tertiary Effectiveness Parameter', 'Tertiary effectiveness endpoint 1: The change in measured EQ-5D-5L scale from baseline at the 6-month', 'visit and 12-month visit.', 'Tertiary effectiveness endpoint 2: The measured Global Perceived Effect scale at the 6-month visit and', '12-month visit.', '12.3.4 Exploratory Analysis', 'Other variables of interest, which include, but are not limited to, WOMAC subscale analysis (pain,', 'stiffness, physical function), change in pain medication usage from baseline as measured by subject self-', 'reported average daily dosage, healthcare utilization, and change in weight from baseline, will be', 'summarized at various visit intervals as discussed below in section 12.5.', 'In addition, the endpoints listed above will also be summarized at 18 and 24 months post treatment.', '12.4 GENERAL CONSIDERATIONS', 'All statistical tests will be two-sided and will be performed at the 5% level of significance, unless otherwise', 'stated in the statistical analysis plan (SAP). Continuous data will be summarized by randomized device', 'assignment and other subset (center, age, etc.) groupings using descriptive statistics (number, mean,', 'median, standard deviation [SD], minimum, and maximum). Categorical data will be summarized by', 'randomized device assignment and other subset groupings using frequency tables (frequencies,', 'percentages, confidence intervals). The natural log transformation will be applied to variables which are', 'highly skewed. If the model assumptions for the ANOVA are not met, transformation of the data or non-', 'parametric analysis may be implemented.', '12.5 DEMOGRAPHICS, BASELINE CHARACTERISTICS, AND CONCOMITANT', 'MEDICATIONS', 'Demographic data, medical history, and concomitant medications will be summarized by means of', 'descriptive statistics.', 'Version #: 4.0', 'Page 39 of 62', 'Version Date: 28Mar19']['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', '12.6 EFFECTIVENESS ANALYSES', '12.6.1 Primary Effectiveness Analysis', 'The primary efficacy parameter is the response rate which is defined as the proportion of subjects whose', 'knee pain is reduced from baseline by > 50% based on the NRS scale at 6 months after treatment.', \"Each subject's response to the treatment will be treated as an independent binomial event:\", 'Ho: TTC - TTT > 0.05', 'Ha: TTC - TTT < 0.05', 'Where:', 'NT: proportion of subjects with > 50% decrease from baseline in NRS pain score from baseline at the 6', 'months post randomization in the CRFA group', 'nc. proportion of subjects with > than 50% decrease from baseline in NRS score from Screening at the 6', 'months post randomization in the HA injection group', 'The non-inferiority margin is set at 5% for the primary efficacy parameter expressed as proportion. The', 'difference of proportions between treatment groups will be calculated and a two sided 95% confidence', 'interval will be constructed using Wald asymptotic confidence limits approach or exact binomial limits', 'approach. If the upper bound is less than 0.05, then \"Non-inferiority\\' is established for the CRFA group', 'relative to the HA injection group. If, in addition, the upper bound of the confidence interval is below zero,', 'the CRFA group can be determined to be \"Superior\\' to the HA injection group.', 'Treatment by study center interaction may be examined graphically across study center to determine the', 'association between treatment and response rate is in the same direction or using logistic regression with', 'response rate at 6 months as the response variable, and the study center, treatment group, study center', 'by treatment group interaction as predictor variables in the model.', '12.6.2 Secondary Effectiveness Analysis', 'If the null hypothesis is rejected for the primary endpoint, i.e., CRFA is concluded to be either non-inferior', 'or superior to the HA injection, the secondary endpoints will be compared between treatment groups as', 'detailed below.', '12.6.2.1', 'Knee Pain Reduction', 'Version #: 4.0', 'Page 40 of 62', 'Version Date: 28Mar19']['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', 'The proportion of subjects whose knee pain is reduced from baseline by > 50% based on the Numeric', 'Rating Scale (NRS) at the 12 month will be calculated and compared between the two treatment groups', 'and within each group as described in section 12.7.1 for the primary endpoint. The method for controlling', 'the secondary endpoint familywise error rate will be detailed in the SAP.', '12.6.2.2', 'WOMAC', 'The change in the WOMAC Score from baseline to the 6 month and 12 month visits will be calculated and', 'compared between the two treatment groups:', 'Ho: 1 = 2', 'Ha: 1 # 2', 'Where:', '11: mean of WOMAC Score change between the Baseline and the Follow-Up at 6 months and 12 months', 'for the CRFA group', '2: mean of WOMAC Score change between the Baseline and the Follow-Up at 6 months and 12 months', 'for the HA injection group', 'Analysis of variance (ANOVA) with treatment as fixed effect and study center as block effect on changes', 'in the WOMAC between the Baseline and the Follow-Up at 6 months and 12 months separately will be', 'performed for the comparison of the CRFA with the HA injection groups.', 'Treatment by study center interaction may be examined using analysis of variance (ANOVA) with', 'treatment, study center and treatment by study center interaction effects on changes in the WOMAC', 'between the baseline and the Follow-Up at 6 months and 12 months in the model.', '12.6.3 Tertiary Effectiveness Analysis', 'The change in the EQ-5D-5L Score from baseline to the 6 month and 12 month visits will be calculated', 'and compared between the two treatment groups:', 'Ho: 1 = 2', 'Ha: 1 # 2', 'Where:', 'Version #: 4.0', 'Page 41 of 62', 'Version Date: 28Mar19']\n\n###\n\n", "completion": "END"}